MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.94 -0.99 (-1.98%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
News headline image
$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings: 
Via Benzinga
News headline image
3 Cathie Wood Stocks to Count on in Q2 ↗
These Cathie Wood Stocks have their risks but offer a massive upside potential ahead, especially if you can handle the volatility. 
Via InvestorPlace
News headline image
7 Potential Biotech Stocks Buyout Targets in 2022 ↗
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
News headline image
$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
3 Best Stocks to Trade Right Now ↗
Get past the persistently bearish headlines, and you'll find stocks to trade long in emerging bull markets that could be lucrative. 
Via InvestorPlace
News headline image
Fed Rate Hike Rallies Stocks ↗
The Federal Reserve led by Jerome Powell hiked interest rates for the first time in three years causing stocks to rally. 
Via Talk Markets
News headline image
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.95% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have... 
Via Benzinga
News headline image
3 Ark Invest Most-Shorted Stocks to Buy ↗
These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers. 
Via InvestorPlace
News headline image
7 Cathie Wood Stocks That Are Worth Buying in March ↗
Many Cathie Wood stocks have suffered losses over the past year, but these companies will likely see strong gains in the coming quarters. 
Via InvestorPlace
News headline image
3 Cathie Wood Stocks to Buy ↗
Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture. 
Via InvestorPlace
News headline image
Tough Slogging Ahead for Investors, Diversification is Important ↗
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
News headline image
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test ↗
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
Via Investor's Business Daily
News headline image
Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022? ↗
Savvy investors can generate lucrative returns by investing in companies that look like a number of prime takeover targets. 
Via InvestorPlace
News headline image
Why Jim Cramer Believes Sirius XM Is Inexpensive ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ: 
Via Benzinga
News headline image
What Are Whales Doing With CRISPR Therapeutics ↗
A whale with a lot of money to spend has taken a noticeably bullish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 15 strange trades. 
Via Benzinga
News headline image
CRISPR Therapeutics's Return On Capital Employed Insights ↗
Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter. 
Via Benzinga
News headline image
Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal ↗
Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up... 
Via Talk Markets
News headline image
Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have... 
Via Benzinga
News headline image
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
News headline image
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
News headline image
3 Deep Value Moonshots to Ride Out Powell’s Taper Tantrum ↗
These three companies might seem like zombies compared to other investing opportunities, but they'll be robust during the Fed taper. 
Via InvestorPlace
News headline image
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
News headline image
7 Stock Bargains Worth a Look After the Most Recent Pullback ↗
Value investors may choose to buy stocks that are out of favor and from among beaten up stock bargains in a variety of sectors. 
Via InvestorPlace
News headline image
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
News headline image
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
News headline image
10 Bargain Stocks to Buy After Falling 30% in 2021 ↗
If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill. 
Via InvestorPlace
News headline image
Biotech Playbook 2021: No Help From Small Caps In Q4 ↗
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story